EXAS Return on Equity (ROE) Analysis
Higher than 23% of Healthcare sector peers
Updated 2555h ago·SEC filings & market data
Key Takeaway
EXAS (EXAS) has a Return on Equity (ROE) of -8.7% as of May 2026.
Sector Performance
23th percentileEXAS
-8.7%
Sector Median
10.1%
Sector Avg
68.8%
Deep Analysis
EXAS (EXAS) has a Return on Equity (ROE) of -8.7% as of May 2026.
This places EXAS in the 23th percentile of the Healthcare sector, which has a median Return on Equity (ROE) of 10.1% and a sector average of 68.8%. EXAS's Return on Equity (ROE) is 186.1% below the sector median, a significant divergence that warrants closer examination. In context: ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about EXAS?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
How does EXAS's Return on Equity (ROE) compare to its sector?
EXAS's Return on Equity (ROE) of -8.7% compares to a Healthcare sector median of 10.1%, placing it in the 23th percentile.
Who are EXAS's closest peers by Return on Equity (ROE)?
The closest Healthcare peers by Return on Equity (ROE) include: ALGN (10.1%), TECH (9.0%), BIIB (7.7%), ABT (12.5%), TMO (13.5%).
Learn More About Return on Equity (ROE)
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master EXAS's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full EXAS research report →EXAS
-8.7%
Sector Median
10.1%
Sector Avg
68.8%
How EXAS's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.